Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore

PURPOSE: Reducing the risk of exacerbation is a long-term goal of managing moderate-to-severe asthma. The use of fluticasone propionate/formoterol fumarate dihydrate (FP/FORM) pressurized metered-dose (pMDI, Flutiform(®)), a type of inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) fixe...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisseau, Sebastien, Qasuri, Murtaza, Ho, Weng Tong, Ghosh, Wrik, Hadjiat, Yacine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547776/
https://www.ncbi.nlm.nih.gov/pubmed/33116696
http://dx.doi.org/10.2147/CEOR.S262267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547776/
https://www.ncbi.nlm.nih.gov/pubmed/33116696
http://dx.doi.org/10.2147/CEOR.S262267

Ejemplares similares